Novartis edges Roche in targeted melanoma with Tafinlar-Mekinist adjuvant 'breakthrough'
admin 23rd October 2017 Uncategorised 0Score one for Novartis in its quest to expand its cancer-fighting combo, Tafinlar and Mekinist. On Monday, the FDA bestowed its “breakthrough” tag on the pair in adjuvant, BRAF V600 mutation-positive melanoma, setting it up for a quick trip down the regulatory path to approval.
More: Novartis edges Roche in targeted melanoma with Tafinlar-Mekinist adjuvant 'breakthrough'
Source: fierce